Executive Development Programme in Pharma Safety and Risk Assessment

-- ViewingNow

The Executive Development Programme in Pharma Safety and Risk Assessment is a comprehensive certificate course designed to equip learners with critical skills in pharmaceutical safety and risk management. This programme is essential for professionals seeking to advance their careers in the pharmaceutical industry, where safety and risk assessment are paramount.

5.0
Based on 7,394 reviews

5,748+

Students enrolled

GBP £ 140

GBP £ 202

Save 44% with our special offer

Start Now

ๅ…ณไบŽ่ฟ™้—จ่ฏพ็จ‹

The course covers key topics such as pharmacovigilance, benefit-risk assessment, risk management plans, and regulatory affairs. Learners will gain a deep understanding of the drug development process, from pre-clinical to post-marketing phases, and how to manage risks effectively. With the increasing demand for skilled professionals in pharmaceutical safety and risk assessment, this course provides a competitive edge for career advancement. Learners will develop essential skills in identifying, assessing, and managing risks, making them valuable assets in the pharmaceutical industry. In summary, this Executive Development Programme in Pharma Safety and Risk Assessment is a crucial investment for professionals seeking to excel in the pharmaceutical industry. By providing a solid foundation in safety and risk assessment, this course empowers learners to make informed decisions, mitigate risks, and advance their careers in a rapidly evolving industry.

100%ๅœจ็บฟ

้šๆ—ถ้šๅœฐๅญฆไน 

ๅฏๅˆ†ไบซ็š„่ฏไนฆ

ๆทปๅŠ ๅˆฐๆ‚จ็š„LinkedInไธชไบบ่ต„ๆ–™

2ไธชๆœˆๅฎŒๆˆ

ๆฏๅ‘จ2-3ๅฐๆ—ถ

้šๆ—ถๅผ€ๅง‹

ๆ— ็ญ‰ๅพ…ๆœŸ

่ฏพ็จ‹่ฏฆๆƒ…

โ€ข Introduction to Pharma Safety and Risk Assessment: Understanding the importance of safety and risk assessment in the pharmaceutical industry, key terminologies, and the regulatory framework.
โ€ข Pharmacovigilance: The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem.
โ€ข Risk Management: Identifying and assessing risks, determining risk tolerance, and implementing strategies to mitigate or manage those risks.
โ€ข Clinical Trial Safety: Ensuring the safety of participants in clinical trials, including the design of safety monitoring plans, reporting of safety data, and safety-related decisions during the trial.
โ€ข Pharmacokinetics and Drug Metabolism: Understanding the movement of drugs in the body, including absorption, distribution, metabolism, and excretion, and how these processes can impact drug safety.
โ€ข Adverse Event Reporting and Management: Identifying, reporting, and managing adverse events, including serious adverse events, in a timely and effective manner.
โ€ข Safety Signal Detection and Evaluation: Identifying and evaluating safety signals, including the use of statistical tools and methods.
โ€ข Regulatory Inspections and Audits: Preparing for and managing regulatory inspections and audits, including the development of Standard Operating Procedures (SOPs) and quality management systems.
โ€ข Risk Communication: Communicating safety and risk information effectively to stakeholders, including healthcare professionals, patients, and regulatory authorities.
โ€ข Crisis Management: Managing crises related to drug safety, including the development of crisis management plans, communication strategies, and lessons learned.

่Œไธš้“่ทฏ

ๅ…ฅๅญฆ่ฆๆฑ‚

  • ๅฏนไธป้ข˜็š„ๅŸบๆœฌ็†่งฃ
  • ่‹ฑ่ฏญ่ฏญ่จ€่ƒฝๅŠ›
  • ่ฎก็ฎ—ๆœบๅ’Œไบ’่”็ฝ‘่ฎฟ้—ฎ
  • ๅŸบๆœฌ่ฎก็ฎ—ๆœบๆŠ€่ƒฝ
  • ๅฎŒๆˆ่ฏพ็จ‹็š„ๅฅ‰็Œฎ็ฒพ็ฅž

ๆ— ้œ€ไบ‹ๅ…ˆ็š„ๆญฃๅผ่ต„ๆ ผใ€‚่ฏพ็จ‹่ฎพ่ฎกๆณจ้‡ๅฏ่ฎฟ้—ฎๆ€งใ€‚

่ฏพ็จ‹็Šถๆ€

ๆœฌ่ฏพ็จ‹ไธบ่Œไธšๅ‘ๅฑ•ๆไพ›ๅฎž็”จ็š„็Ÿฅ่ฏ†ๅ’ŒๆŠ€่ƒฝใ€‚ๅฎƒๆ˜ฏ๏ผš

  • ๆœช็ป่ฎคๅฏๆœบๆž„่ฎค่ฏ
  • ๆœช็ปๆŽˆๆƒๆœบๆž„็›‘็ฎก
  • ๅฏนๆญฃๅผ่ต„ๆ ผ็š„่กฅๅ……

ๆˆๅŠŸๅฎŒๆˆ่ฏพ็จ‹ๅŽ๏ผŒๆ‚จๅฐ†่Žทๅพ—็ป“ไธš่ฏไนฆใ€‚

ไธบไป€ไนˆไบบไปฌ้€‰ๆ‹ฉๆˆ‘ไปฌไฝœไธบ่Œไธšๅ‘ๅฑ•

ๆญฃๅœจๅŠ ่ฝฝ่ฏ„่ฎบ...

ๅธธ่ง้—ฎ้ข˜

ๆ˜ฏไป€ไนˆ่ฎฉ่ฟ™้—จ่ฏพ็จ‹ไธŽๅ…ถไป–่ฏพ็จ‹ไธๅŒ๏ผŸ

ๅฎŒๆˆ่ฏพ็จ‹้œ€่ฆๅคš้•ฟๆ—ถ้—ด๏ผŸ

WhatSupportWillIReceive

IsCertificateRecognized

WhatCareerOpportunities

ๆˆ‘ไป€ไนˆๆ—ถๅ€™ๅฏไปฅๅผ€ๅง‹่ฏพ็จ‹๏ผŸ

่ฏพ็จ‹ๆ ผๅผๅ’Œๅญฆไน ๆ–นๆณ•ๆ˜ฏไป€ไนˆ๏ผŸ

่ฏพ็จ‹่ดน็”จ

ๆœ€ๅ—ๆฌข่ฟŽ
ๅฟซ้€Ÿ้€š้“๏ผš GBP £140
1ไธชๆœˆๅ†…ๅฎŒๆˆ
ๅŠ ้€Ÿๅญฆไน ่ทฏๅพ„
  • ๆฏๅ‘จ3-4ๅฐๆ—ถ
  • ๆๅ‰่ฏไนฆไบคไป˜
  • ๅผ€ๆ”พๆณจๅ†Œ - ้šๆ—ถๅผ€ๅง‹
Start Now
ๆ ‡ๅ‡†ๆจกๅผ๏ผš GBP £90
2ไธชๆœˆๅ†…ๅฎŒๆˆ
็ตๆดปๅญฆไน ่Š‚ๅฅ
  • ๆฏๅ‘จ2-3ๅฐๆ—ถ
  • ๅธธ่ง„่ฏไนฆไบคไป˜
  • ๅผ€ๆ”พๆณจๅ†Œ - ้šๆ—ถๅผ€ๅง‹
Start Now
ไธคไธช่ฎกๅˆ’้ƒฝๅŒ…ๅซ็š„ๅ†…ๅฎน๏ผš
  • ๅฎŒๆ•ด่ฏพ็จ‹่ฎฟ้—ฎ
  • ๆ•ฐๅญ—่ฏไนฆ
  • ่ฏพ็จ‹ๆๆ–™
ๅ…จๅŒ…ๅฎšไปท โ€ข ๆ— ้š่—่ดน็”จๆˆ–้ขๅค–่ดน็”จ

่Žทๅ–่ฏพ็จ‹ไฟกๆฏ

ๆˆ‘ไปฌๅฐ†ๅ‘ๆ‚จๅ‘้€่ฏฆ็ป†็š„่ฏพ็จ‹ไฟกๆฏ

ไปฅๅ…ฌๅธ่บซไปฝไป˜ๆฌพ

ไธบๆ‚จ็š„ๅ…ฌๅธ็”ณ่ฏทๅ‘็ฅจไปฅๆ”ฏไป˜ๆญค่ฏพ็จ‹่ดน็”จใ€‚

้€š่ฟ‡ๅ‘็ฅจไป˜ๆฌพ

่Žทๅพ—่Œไธš่ฏไนฆ

็คบไพ‹่ฏไนฆ่ƒŒๆ™ฏ
EXECUTIVE DEVELOPMENT PROGRAMME IN PHARMA SAFETY AND RISK ASSESSMENT
ๆŽˆไบˆ็ป™
ๅญฆไน ่€…ๅง“ๅ
ๅทฒๅฎŒๆˆ่ฏพ็จ‹็š„ไบบ
London School of International Business (LSIB)
ๆŽˆไบˆๆ—ฅๆœŸ
05 May 2025
ๅŒบๅ—้“พID๏ผš s-1-a-2-m-3-p-4-l-5-e
ๅฐ†ๆญค่ฏไนฆๆทปๅŠ ๅˆฐๆ‚จ็š„LinkedInไธชไบบ่ต„ๆ–™ใ€็ฎ€ๅކๆˆ–CVไธญใ€‚ๅœจ็คพไบคๅช’ไฝ“ๅ’Œ็ปฉๆ•ˆ่ฏ„ไผฐไธญๅˆ†ไบซๅฎƒใ€‚
SSB Logo

4.8
ๆ–ฐๆณจๅ†Œ